EFG PH20 SC ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 162 | 類天疱瘡（後天性表皮水疱症を含む。） | 1 |
162. 類天疱瘡（後天性表皮水疱症を含む。）
臨床試験数 : 83 / 薬物数 : 128 - (DrugBank : 51) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05267600 (ClinicalTrials.gov) | March 2022 | 14/2/2022 | A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD) | A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | Bullous Pemphigoid | Biological: EFG PH20 SC;Other: PBO;Drug: Prednisone | argenx | NULL | Not yet recruiting | 18 Years | N/A | All | 160 | Phase 2/Phase 3 | NULL |